ReviewCurrent neurology and neuroscience reports2007
The role of dendritic cells in multiple sclerosis.
Review in Current neurology and neuroscience reports, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Overview of dendritic cells subsets and their involvement in immune-related pathological disease.BioImpacts : BI · 2025Review
- Apigenin Modulates Dendritic Cell Activities and Curbs Inflammation Via RelB Inhibition in the Context of Neuroinflammatory Diseases.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2021Article
- Potential Role of Flavonoids in Treating Chronic Inflammatory Diseases with a Special Focus on the Anti-Inflammatory Activity of Apigenin.Antioxidants (Basel, Switzerland) · 2019Review
- MicroRNA signature of central nervous system-infiltrating dendritic cells in an animal model of multiple sclerosis.Immunology · 2018Article
- Dendritic Cells as an Alternate Approach for Treatment of Neurodegenerative Disorders.Cellular and molecular neurobiology · 2018Review
- Diversity of immune cell types in multiple sclerosis and its animal model: Pathological and therapeutic implications.Journal of neuroscience research · 2017Review
- Immethridine, histamine HOncotarget · 2017Article
- GYF-21, an Epoxide 2-(2-Phenethyl)-Chromone Derivative, Suppresses Innate and Adaptive Immunity via Inhibiting STAT1/3 and NF-κB Signaling Pathways.Frontiers in pharmacology · 2017Article
- Apigenin, a Natural Flavonoid, Attenuates EAE Severity Through the Modulation of Dendritic Cell and Other Immune Cell Functions.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2016Article
- Role of the immunogenic and tolerogenic subsets of dendritic cells in multiple sclerosis.Mediators of inflammation · 2015Review
- Apolipoprotein E mediation of neuro-inflammation in a murine model of multiple sclerosis.Journal of neuroimmunology · 2014Article
- Natural killer cells and their receptors in multiple sclerosis.Brain : a journal of neurology · 2013Review
- Dendritic cells a double-edge sword in autoimmune responses.Frontiers in immunology · 2012Article
- Article
- Limited sufficiency of antigen presentation by dendritic cells in models of central nervous system autoimmunity.Journal of autoimmunity · 2011Article
- IFN-beta inhibits dendritic cell migration through STAT-1-mediated transcriptional suppression of CCR7 and matrix metalloproteinase 9.Journal of immunology (Baltimore, Md. : 1950) · 2010Article
- PPAR-gamma: Therapeutic Potential for Multiple Sclerosis.PPAR research · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although multiple sclerosis (MS) is a presumed T-cell- mediated disease, it is unclear what triggers the development of neuroantigen-specific T cells. Autoreactive CD4(+) T cells are activated by antigen presenting cells; dendritic cells (DCs) are the primary antigen presenting cells directing T-cell functions and are, therefore, extremely important in directing the immune pathology characteristic of MS. Three important concepts have emerged regarding DCs in MS. First, DCs are present within the healthy central nervous system (CNS) in association with the cerebrospinal fluid space and microvasculature. Therefore, the potential for sampling of CNS antigens in similar fashion to other tissues and organs exists and likely plays an integral role in CNS immunity. The degree of involvement, as well as the source, of these CNS DCs has been addressed by several studies using the experimental autoimmune encephalomyelitis animal model. Second, DCs are found within MS lesions and have been shown to be functionally abnormal in patients with MS. Lastly, therapeutics directed at DCs could potentially be engineered for treatment in MS and in fact may already be involved in the mechanisms of current immunomodulatory therapies.
Indexed as
Identifiers
17488591What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.